>
Switch to:

Illumina Long-Term Debt

: $1,241 Mil (As of Mar. 2022)
View and export this data going back to 2000. Start your Free Trial

Illumina's Long-Term Debt for the quarter that ended in Mar. 2022 was $1,241 Mil.

Illumina's quarterly Long-Term Debt increased from Sep. 2021 ($1,687 Mil) to Dec. 2021 ($1,695 Mil) but then declined from Dec. 2021 ($1,695 Mil) to Mar. 2022 ($1,241 Mil).

Illumina's annual Long-Term Debt declined from Dec. 2019 ($1,141 Mil) to Dec. 2020 ($673 Mil) but then increased from Dec. 2020 ($673 Mil) to Dec. 2021 ($1,695 Mil).

Illumina Long-Term Debt Historical Data

The historical data trend for Illumina's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Long-Term Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,182.00 890.00 1,141.00 673.00 1,695.00

Illumina Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Long-Term Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,672.00 1,679.00 1,687.00 1,695.00 1,241.00

Illumina  (NAS:ILMN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Illumina Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Illumina's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina Business Description

Illumina logo
Industry
Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071
Comparable Companies
XSWX:LONN SHSE:603259 NYSE:IQV NAS:IDXX NYSE:A NYSE:MTD NYSE:LH NYSE:PKI XPAR:ERF NAS:ICLR
Traded in Other Exchanges
ILMN:Mexico 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany I1LM34:Brazil ILMN:Austria
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Website
https://www.illumina.com
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
Flatley Jay T director 9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H officer: SVP Product Development 5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles officer: SVP & General Counsel 5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A director, officer: President and CEO 350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark officer: SVP Chief Commercial Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P officer: SVP, Global Quality & Ops PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K officer: VP, Chief Accounting Officer INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L officer: SVP, Chief People Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa officer: SVP, Entrepreneurial Devlopmt 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E director 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell director C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

From GuruFocus

Financial Consulate, Inc Buys iShares J.P. Morgan EM Corporate Bond ETF, Exxon Mobil Corp, Royalty Pharma PLC, Sells Invesco S&P 500 Equal Weight Financials ETF, Vanguard S&P 500 ETF, CrowdStrike Holdings Inc

By insider 02-07-2022

Illumina Supports Norway's Pioneering Precision Medicine Study

By PRNewswire 12-09-2021

Telos Capital Management, Inc. Buys Illumina Inc, United Parcel Service Inc, Newell Brands Inc, Sells Activision Blizzard Inc, iShares Biotechnology ETF, Merck Inc

By insider 01-21-2022

Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

By Business Wire 01-10-2022

Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications

By PRNewswire 03-16-2022

Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe

By PRNewswire 03-15-2022

Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices

By GuruFocusNews 01-04-2022

Geo Capital Gestora de Recursos Ltd Buys Illumina Inc, Deere, Meta Platforms Inc, Sells Cerner Corp, Marriott International Inc, Palo Alto Networks Inc

By insider 02-15-2022

Illumina to Announce Fourth Quarter & Full Year 2021 Financial Results on Thursday, February 10, 2022

By PRNewswire 01-20-2022

GRAIL and Premier's PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

By Business Wire 01-10-2022

Other Sources

$ILMN - Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Cowen Health Care Conference (Transcript).…

By Seekingalpha 2022-03-07

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

By Zacks 2022-02-10

4 Toxic Stocks to Eliminate From Your Portfolio Now

By Zacks 2021-12-27

Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics

By Zacks 2022-01-07

OTR Global Upgrades Illumina (ILMN) to Buy

By tipranks.com 2022-03-30

Illumina (ILMN) to Address Nasopharynx Cancer With New Pact

By Zacks 2022-02-07

Here's Why You Should Retain Illumina (ILMN) Stock For Now

By Zacks 2022-03-14

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

By Zacks 2022-02-03

Illumina (ILMN) Invests in Seven Additional Genomics Startups

By Zacks 2022-03-18

Why Illumina Stock Just Jumped 9.5%

By Fool 2022-01-11

Here's Why You Should Hold on to Illumina (ILMN) for Now

By Zacks 2022-01-14

Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates

By Zacks 2022-02-10

Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

By Zacks 2022-01-05

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

By Zacks 2021-12-15

Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View

By Zacks 2022-01-11

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)